-With Amendment X, to determine the ability of autologous TIL infused after minimal in vitro culture in conjunction with high dose aldesleukin following a non-myeloablative lymphodepleting preparative regimen and then the addition of anti-PD-1 at time of progressive disease per RECIST criteria to mediate tumor regression in patients with metastatic cancers.